What MRD test was used in MD-01?

What MRD test was used in MD-01?

• A. Guardant360
• B. CAPP-Seq
• C. Precise MRD
• D. Signatera

Answer: (C)

Minimal residual disease detection hinges on tracking tumor-derived DNA in blood with very deep sequencing. In MD-01, the MRD assessment used Precise MRD, a tumor-informed, patient-specific assay that identifies the patient’s tumor mutations and then monitors those exact mutations in plasma after treatment. By focusing on a personalized set of mutations and sequencing them at ultra-deep depth, it achieves high sensitivity for detecting very low levels of circulating tumor DNA, which signals residual disease or early relapse. Broad panels like Guardant360 are designed for general mutation profiling and aren’t optimized for the ultra-deep, targeted detection needed for MRD. CAPP-Seq describes a MRD-focused sequencing approach, but the trial specifically used Precise MRD. Signatera is another tumor-informed MRD test, but MD-01 employed Precise MRD in this context.

Minimal residual disease detection hinges on tracking tumor-derived DNA in blood with very deep sequencing. In MD-01, the MRD assessment used Precise MRD, a tumor-informed, patient-specific assay that identifies the patient’s tumor mutations and then monitors those exact mutations in plasma after treatment. By focusing on a personalized set of mutations and sequencing them at ultra-deep depth, it achieves high sensitivity for detecting very low levels of circulating tumor DNA, which signals residual disease or early relapse.

Broad panels like Guardant360 are designed for general mutation profiling and aren’t optimized for the ultra-deep, targeted detection needed for MRD. CAPP-Seq describes a MRD-focused sequencing approach, but the trial specifically used Precise MRD. Signatera is another tumor-informed MRD test, but MD-01 employed Precise MRD in this context.